Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease (AEROBIC)
Primary Purpose
Healthy Aging, Alzheimer Disease
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Aerobic Exercise
Sponsored by
About this trial
This is an interventional basic science trial for Healthy Aging
Eligibility Criteria
Inclusion Criteria:
- Age 60 and older
- Stable medication doses (>1month)
- Post-menopausal
- Diagnosis of either Nondemented (CDR 0) or Probable AD (CDR 0.5 or 1 only)
Exclusion Criteria:
- Inability to provide consent
- Diagnosis of insulin-dependent (Type 1) Diabetes Mellitus
- Recent ischemic heart disease (<2 years)
- Diagnosis of an clinically significant chronic disease including cardiovascular disease (CVD), other metabolic diseases (e.g., thyroid), cancer, human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome
- Excluded from or unable to complete an MRI scan
- Any Neurological disorders that have the potential to impair cognition or brain metabolism (e.g., Parkinson's disease, stroke defined as a clinical episode with neuroimaging evidence in an appropriate area to explain the symptoms).
- Clinically significant depressive symptoms that may impair cognition, abnormalities in B12, rapid plasma regain (RPR), or thyroid function that may impair cognition, use of psychoactive and investigational medications, and significant visual or auditory impairment
Sites / Locations
- Univeristy of Kansas Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Moderate Intensity Aerobic Exercise
High Intensity Aerobic Exercise
Arm Description
45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.55 + Resting HR
65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.75 + Resting HR
Outcomes
Primary Outcome Measures
Fluorodeoxyglucose (FDG) positron emission tomography (PET) Metabolism (Standard Uptake Value Ratio)
FDG PET measures reflecting cerebral metabolism standardized to the uptake value of the cerebellum and standardized uptake value ratios (SUVR) will be calculated from native-space region of interest (ROI).
Secondary Outcome Measures
Lactate Area Under the Curve
Change in circulating lactate
Brain-derived neurotrophic factor (BDNF) Change
Change in circulating Brain Derived Neurotrophic Factor
Full Information
NCT ID
NCT04299308
First Posted
March 4, 2020
Last Updated
November 1, 2022
Sponsor
University of Kansas Medical Center
Collaborators
National Institute on Aging (NIA)
1. Study Identification
Unique Protocol Identification Number
NCT04299308
Brief Title
Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease
Acronym
AEROBIC
Official Title
Acute Exercise Response On Brain Imaging and Cognition
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 28, 2020 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Kansas Medical Center
Collaborators
National Institute on Aging (NIA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The overall goal is to characterize the acute exercise response as it relates to brain glucose metabolism in aging and Alzheimer's Disease (AD). The study team will also examine lactate metabolism, relationships with cognition, and the effect of exercise intensity.
Detailed Description
Aim 1: Compare the effects of acute, moderate intensity and acute, higher intensity exercise on cerebral glucose metabolism in nondemented (ND) elderly and AD subjects. ND (n=30) and AD (n=30) subjects will undergo a single bout of moderate intensity (45-55% HRR) or higher intensity (65-75% HRR) exercise to assess the effect of exercise intensity on acute change in brain glucose metabolism (rest to exercise). Investigators hypothesize that both moderate and high intensity exercise will elicit a drop in global brain glucose metabolism compared to quiet rest, but that the effect will be greater with higher intensity vs. moderate intensity exercise, and greater in ND subjects than in AD subjects.
Aim 2: Characterize the effect of both exercise intensities on acute biomarker response and cognition (memory and executive function) in ND and AD subjects. The acute biomarker response to exercise and the effect on cognition has not been examined in aged or AD cohorts. Investigators hypothesize that acute higher intensity exercise will elicit a greater blood lactate response (area under the curve, AUC) compared to acute moderate intensity exercise, and that this response will be greater in ND than in AD subjects. Investigators further hypothesize that lactate AUC will track negatively with change in cerebral glucose metabolism and cognitive performance. Although investigators will focus on lactate, they will also quantify additional exercise-related biomarkers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Aging, Alzheimer Disease
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
2 arm, cross-sectional
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Moderate Intensity Aerobic Exercise
Arm Type
Experimental
Arm Description
45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.55 + Resting HR
Arm Title
High Intensity Aerobic Exercise
Arm Type
Experimental
Arm Description
65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.75 + Resting HR
Intervention Type
Behavioral
Intervention Name(s)
Aerobic Exercise
Intervention Description
Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
Primary Outcome Measure Information:
Title
Fluorodeoxyglucose (FDG) positron emission tomography (PET) Metabolism (Standard Uptake Value Ratio)
Description
FDG PET measures reflecting cerebral metabolism standardized to the uptake value of the cerebellum and standardized uptake value ratios (SUVR) will be calculated from native-space region of interest (ROI).
Time Frame
Resting Vs acute exercise bout: ~1 month
Secondary Outcome Measure Information:
Title
Lactate Area Under the Curve
Description
Change in circulating lactate
Time Frame
Resting Vs acute exercise bout: ~1 month
Title
Brain-derived neurotrophic factor (BDNF) Change
Description
Change in circulating Brain Derived Neurotrophic Factor
Time Frame
Resting Vs acute exercise bout: ~1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 60 and older
Stable medication doses (>1month)
Post-menopausal
Diagnosis of either Nondemented (CDR 0) or Probable AD (CDR 0.5 or 1 only)
Exclusion Criteria:
Inability to provide consent
Diagnosis of insulin-dependent (Type 1) Diabetes Mellitus
Recent ischemic heart disease (<2 years)
Diagnosis of an clinically significant chronic disease including cardiovascular disease (CVD), other metabolic diseases (e.g., thyroid), cancer, human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome
Excluded from or unable to complete an MRI scan
Any Neurological disorders that have the potential to impair cognition or brain metabolism (e.g., Parkinson's disease, stroke defined as a clinical episode with neuroimaging evidence in an appropriate area to explain the symptoms).
Clinically significant depressive symptoms that may impair cognition, abnormalities in B12, rapid plasma regain (RPR), or thyroid function that may impair cognition, use of psychoactive and investigational medications, and significant visual or auditory impairment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jill Morris
Phone
913-945-7675
Email
jmorris2@kumc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Casey John
Phone
913-945-7672
Email
cjohn@kumc.edu
Facility Information:
Facility Name
Univeristy of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jill Morris
Phone
913-945-7675
Email
morrisj2@kumc.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease
We'll reach out to this number within 24 hrs